StreetInsider.com News Articles

Form DEF 14A Rezolute, Inc. For: Dec 02

Wed, 21 Oct 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20261021/27217106.html

H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)

Thu, 15 Oct 2026 07:12:51 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $10.00 price target on Rezolute (NASDAQ: RZLT).

The analyst commented: "Rezolute announced that its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism (HI) has completed enrollment of all 16 patients, with topline results now expected in mid-December 2026, providing greater visibility into the company's most important near-term catalyst. Recall, seven of the first eight patients have already met the primary responder criterion of at least a 50% reduction in intravenous (IV) glucose requirements during the eight-week pivotal treatment period, with all seven achieving complete discontinuation of IV glucose. The eighth

Rezolute (RZLT) Reiterated at Market Outperform by Citizens - 'upLIFT Results Locked in for Mid-December'

Thu, 15 Oct 2026 05:12:58 -0400

Citizens analyst Jason Butler reiterated a Market Outperform rating and $15.00 price target on Rezolute (NASDAQ: RZLT).

The analyst commented, "upLIFT results locked in for mid-December, and we remain confident in a positive outcome; we reiterate our Market Outperform rating and $15 risk-adjusted, DCF-derived price target on Rezolute. Yesterday afternoon, Rezolute announced that enrollment has been completed in the ongoing Phase 3 trial evaluating ersodetug in tumor hyperinsulinism (tHI). The company clarified its expectation for top-line results to be announced in mid-December (vs. prior 4Q26). Our confidence in positive results is driven by the interim results announced in June 2026 as

Form 8-K Rezolute, Inc. For: Oct 14

Wed, 14 Oct 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20261014/27187876.html

Rezolute completes enrollment in Phase 3 tumor hyperinsulinism study

Wed, 14 Oct 2026 16:05:13 -0400

Rezolute, Inc. (NASDAQ: RZLT) announced the completion of enrollment in its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism (HI), with topline results expected in mid-December 2026.

The upLIFT study is a single-arm, open-label trial enrolling 16 participants with insulinoma or non-islet cell tumors who have uncontrolled hypoglycemia caused by tumor HI. The primary endpoint measures the proportion of participants requiring intravenous glucose who achieve at least a 50% reduction from baseline in glucose infusion rate during an 8-week pivotal treatment phase. For statistical significance, the lower bound of the 95% confidence interval for the responder rate must be at

Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Wed, 14 Oct 2026 16:05:00 -0400

Topline results expected mid-December 2026

REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that the open-label Phase 3 study of ersodetug in tumor HI (upLIFT) is now fully enrolled and topline data are expected mid-December 2026. The Company plans to continue its expanded access program for purposes of providing ersodetug on a compassionate use basis to individuals living with serious and refractory hypoglycemia due to tumor HI.

The upLIFT

Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Wed, 14 Oct 2026 16:05:00 -0400

Topline results expected mid-December 2026

The upLIFT

Form PRE 14A Rezolute, Inc. For: Dec 02

Wed, 07 Oct 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20261007/27161965.html

Rezolute (RZLT) PT Raised to $12 at Lake Street

Tue, 06 Oct 2026 08:52:43 -0400

Lake Street analyst Daniel Brims raised the price target on Rezolute (NASDAQ: RZLT) to $12.00 (from $9.00) while maintaining a Buy rating.

H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)

Tue, 06 Oct 2026 06:57:23 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $10.00 price target on Rezolute (NASDAQ: RZLT).

The analyst commented: "FDA opens a potential BLA path for congenital HI; upLIFT readout remains the next near-term catalyst. Rezolute (RZLT; Buy) announced that, following its preliminary review of the detailed Phase 3 sunRIZE dataset, FDA recommended that the company request a Type B pre-BLA meeting as a precursor to submitting a BLA for ersodetug in congenital hyperinsulinism (cHI). We view the update as meaningfully positive from a regulatory perspective, as FDA has now reviewed the CGM source and analysis datasets submitted in June

Rezolute (RZLT) PT Raised to $15 at Citizens Post Positive FDA Feedback on cHI Ph3 Data

Tue, 06 Oct 2026 05:37:30 -0400

Citizens analyst Jason Butler raised the price target on Rezolute (NASDAQ: RZLT) to $15.00 (from $11.00) while maintaining a Market Outperform rating.

The analyst commented, " Positive FDA feedback following preliminary review of cHI Phase 3 data supports anticipated BLA submission; we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target on Rezolute to $15 from $11. This morning, Rezolute announced that it has received feedback from FDA on the regulatory path for ersodetug in congenital hyperinsulinism (cHI). The FDA recommended a pre-BLA meeting as a precursor to submitting a BLA. We view this outcome as a clear

Rezolute (RZLT) PT Raised to $15 at Citizens Post Positive FDA Feedback on cHI Ph3 Data

Tue, 06 Oct 2026 05:37:30 -0400

Citizens analyst Jason Butler raised the price target on Rezolute (NASDAQ: RZLT) to $15.00 (from $11.00) while maintaining a Market Outperform rating.

Cantor Fitzgerald Upgrades Rezolute (RZLT) to Overweight

Mon, 05 Oct 2026 16:43:07 -0400

Cantor Fitzgerald analyst Pete Stavropoulos upgraded Rezolute (NASDAQ: RZLT) from Neutral to Overweight.

For an analyst ratings summary and ratings history on Rezolute click here. For more ratings news on Rezolute click here.

Shares of Rezolute closed at $4.01 yesterday.

Form 8-K Rezolute, Inc. For: Oct 05

Mon, 05 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261005/27145932.html

FDA recommends pre-BLA meeting for Rezolute's congenital HI drug

Mon, 05 Oct 2026 07:00:28 -0400

Rezolute, Inc. (Nasdaq: RZLT) announced that the U.S. Food and Drug Administration has recommended a pre-biologics license application (BLA) meeting for ersodetug, the company's investigational treatment for congenital hyperinsulinism (HI), following a preliminary review of data from the Phase 3 sunRIZE study.

The FDA's recommendation comes despite the sunRIZE trial failing to meet its prespecified primary and key secondary endpoints. The study did not show statistically significant reductions in hypoglycemia events measured by finger-stick self-monitored blood glucose compared to placebo. The key secondary endpoint measuring time in hypoglycemia by continuous glucose monitoring (CGM) was also not met at the Week 24

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

Mon, 05 Oct 2026 07:00:00 -0400

The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities

On track to report topline results for the Phase 3 upLIFT study in tumor HI this quarter

REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (“HI”), today announced that following a preliminary review of detailed data from the Phase 3 sunRIZE study of ersodetug for the

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

Mon, 05 Oct 2026 07:00:00 -0400

The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities

On track to report topline results for the Phase 3 upLIFT study in tumor HI this quarter

Lake Street Starts Rezolute (RZLT) at Buy

Wed, 30 Sep 2026 07:40:02 -0400

Lake Street analyst Daniel Brims initiates coverage on Rezolute (NASDAQ: RZLT) with a Buy rating and a price target of $9.00.

For an analyst ratings summary and ratings history on Rezolute click here. For more ratings news on Rezolute click here.

Shares of Rezolute closed at $4.09 yesterday.

Craig-Hallum Upgrades Rezolute (RZLT) to Buy

Tue, 29 Sep 2026 09:41:26 -0400

(Updated - September 29, 2026 9:41 AM EDT)

Craig-Hallum analyst Albert Lowe upgraded Rezolute (NASDAQ: RZLT) from Hold to Buy with a price target of $7.00.

The analyst comments "We are upgrading RZLT to a Buy rating and increasing our price target to $7 in anticipation of positive topline data from ersodetug’s Phase III study in tumor hyperinsulinism (tHI) expected by YE26. • Ersodetug is clearly effective for tumor hyperinsulinism. tHI is an ultra-rare disease (~3K addressable US patients) caused by tumors that produce insulin or IGF-2, leading to persistent hypoglycemia. The severe hypoglycemia often leads to hospitalization and frequently precludes tumor-directed

Craig-Hallum Upgrades Rezolute (RZLT) to Buy

Tue, 29 Sep 2026 09:41:26 -0400

(Updated - September 29, 2026 9:41 AM EDT)

Craig-Hallum analyst Albert Lowe upgraded Rezolute (NASDAQ: RZLT) from Hold to Buy with a price target of $7.00.

Rezolute (RZLT) PT Raised to $10 at H.C. Wainwright

Mon, 28 Sep 2026 07:00:16 -0400

(Updated - September 28, 2026 7:00 AM EDT)

H.C. Wainwright analyst Douglas Tsao raised the price target on Rezolute (NASDAQ: RZLT) to $10.00 (from $5.00) while maintaining a Buy rating.

The analyst commented: "Price target to $10 on upcoming upLIFT catalyst. Management continues to target upLIFT topline results before YE26 and, assuming supportive data, a BLA submission in mid-2027 and 1Q28 launch. Management disclosed, which they previously suggested, that the company now has seven responders in the upLIFT trial. Seven of the first eight patients have now met the response criterion, versus six reported in June. At that time, the seventh responder

Rezolute (RZLT) PT Raised to $10 at H.C. Wainwright

Mon, 28 Sep 2026 07:00:16 -0400

(Updated - September 28, 2026 7:00 AM EDT)

H.C. Wainwright analyst Douglas Tsao raised the price target on Rezolute (NASDAQ: RZLT) to $10.00 (from $5.00) while maintaining a Buy rating.

Rezolute (RZLT) PT Raised to $10 at H.C. Wainwright

Fri, 25 Sep 2026 12:54:06 -0400

H.C. Wainwright analyst Douglas Tsao raised the price target on Rezolute (NASDAQ: RZLT) to $10.00 while maintaining a Buy rating.

Rezolute (RZLT) Reiterated at Market Outperform by Citizens After Q4 Results

Fri, 25 Sep 2026 04:16:33 -0400

Citizens analyst Jason Butler reiterated a Market Outperform rating and $11.00 price target on Rezolute (NASDAQ: RZLT).

The analyst commented, "Top-line results for the tumor-associated hyperinsulinism (tHI) program expected by year-end; we reiterate our Market Outperform rating and $11 risk-adjusted, DCF-derived price target on Rezolute. Yesterday afternoon, Rezolute reported F4Q26 financial results and business updates, reiterating timelines for top-line results from the ongoing Phase 3 upLIFT trial evaluating ersodetug in tumor-associated hyperinsulinism, expected by YE2026. While results from the Phase 3 congenital hyperinsulinism program (CHI) remain under FDA review, the open-label extension phase of the CHI trial is ongoing, and management

Form 10-K Rezolute, Inc. For: Jun 30

Thu, 24 Sep 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260924/27102505.html